Analysis of United States Drug Patent 7,420,069: Scope, Claims, and Landscape
United States Patent 7,420,069, titled "Imidazo[1,2-a]pyridine derivatives," was granted to Merck & Co., Inc. on September 2, 2008. The patent claims a class of compounds and their use in treating various medical conditions. A review of the patent's claims, specifications, and the current patent landscape indicates a primary focus on selective serotonin reuptake inhibitors (SSRIs) and their application in neuropsychiatric disorders.
What Compounds Does Patent 7,420,069 Claim?
The patent asserts broad claims covering novel imidazo[1,2-a]pyridine derivatives. These compounds are characterized by a specific chemical structure designed to interact with biological targets.
Core Chemical Structure
The core of the claimed compounds involves an imidazo[1,2-a]pyridine heterocyclic system. This framework is further substituted at various positions with different functional groups. The patent defines these substitutions with generic formulas (e.g., R¹, R², R³ groups) and provides numerous specific examples illustrating the claimed chemical space.
The general structure described in the patent is as follows:
- Imidazo[1,2-a]pyridine core: A fused bicyclic system containing a pyridine ring fused with an imidazole ring.
- Substituents: The patent details specific allowable substituents at positions 1, 2, 3, 5, 6, 7, and 8 of the imidazo[1,2-a]pyridine nucleus. These substituents include, but are not limited to, alkyl, aryl, heteroaryl, amino, halo, hydroxyl, and alkoxy groups.
Specific Embodiments
The patent provides a detailed list of 112 specific compound examples, each with a unique designation (e.g., Compound 1, Compound 2, etc.) and its corresponding chemical name and structure. These examples represent concrete implementations of the broader generic claims and were likely synthesized and tested by the patent holder.
For instance, Compound 1 is described as 2-(4-fluorophenyl)-3-(4-methylpiperazin-1-ylmethyl)imidazo[1,2-a]pyridine. Compound 2 is 2-(3,4-dichlorophenyl)-3-(4-methylpiperazin-1-ylmethyl)imidazo[1,2-a]pyridine. These specific examples illustrate the variability within the claimed chemical space.
Formulation Claims
Beyond the active pharmaceutical ingredients (APIs) themselves, the patent also includes claims related to pharmaceutical compositions. These claims cover formulations containing the claimed imidazo[1,2-a]pyridine derivatives along with pharmaceutically acceptable carriers, diluents, or excipients. This broadens the scope of protection to the final drug products.
The patent claims include:
- Pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- Methods of preparing such compositions.
What Medical Applications Are Claimed?
The patent claims cover the use of the specified imidazo[1,2-a]pyridine derivatives for the treatment of a range of medical conditions, primarily related to the central nervous system.
Primary Therapeutic Areas
The asserted therapeutic applications are:
- Neuropsychiatric Disorders: This is the primary focus. The patent explicitly mentions the treatment of depression, anxiety disorders, panic disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).
- Other CNS Conditions: The claims also extend to the treatment of conditions such as attention deficit hyperactivity disorder (ADHD), premenstrual dysphoric disorder (PMDD), and climacteric syndrome.
- Pain Management: Certain embodiments of the claimed compounds are suggested for use in treating pain.
Mechanism of Action
The patent indicates that the claimed compounds function as selective serotonin reuptake inhibitors (SSRIs). By inhibiting the reuptake of serotonin in the brain, these compounds are believed to increase extracellular serotonin levels, thereby modulating neurotransmission and alleviating symptoms associated with these disorders.
The patent states: "The compounds of the present invention are SSRIs and are useful in the treatment of CNS disorders, including depression, anxiety, panic disorder, OCD, PTSD, ADHD, PMDD, and climacteric syndrome."
The mechanism involves blocking the serotonin transporter (SERT).
What is the Patent Landscape for 7,420,069?
The patent landscape surrounding US Patent 7,420,069 is characterized by its origin from a major pharmaceutical innovator, its broad claims, and the subsequent development of related or derivative technologies.
Patent Holder and Prosecution History
- Assignee: Merck & Co., Inc. This indicates the patent originated from a significant pharmaceutical research and development entity.
- Filing Date: March 20, 2007 (US Application No. 11/725,951).
- Issue Date: September 2, 2008.
- Term: As a utility patent filed in 2007, its term is generally 20 years from the earliest non-provisional filing date, subject to patent term extensions (PTE) and adjustments. For this patent, the statutory expiration date would be March 20, 2027, barring any extensions.
Prior Art and Inventive Step
During prosecution, patent examiners review existing prior art to determine the novelty and non-obviousness of the claimed inventions. The examiner for US Patent 7,420,069 would have assessed whether the claimed imidazo[1,2-a]pyridine derivatives were adequately distinguished from previously known compounds and their uses. The patent's issuance suggests that the examiner found sufficient novelty and inventive step.
Related Patent Filings
Merck & Co., Inc. has a history of extensive patenting activity in the field of neuropsychiatric drugs. It is common for pharmaceutical companies to file multiple patents covering:
- Core Compound Patents: Like 7,420,069, claiming the novel molecular entities.
- Process Patents: Claiming specific methods for synthesizing the compounds.
- Formulation Patents: Claiming specific dosage forms or delivery systems.
- Method of Use Patents: Claiming new therapeutic applications or specific treatment regimens.
- Polymorph Patents: Claiming specific crystalline forms of the API, which can impact stability, bioavailability, and manufacturing.
A search for Merck-assigned patents related to imidazo[1,2-a]pyridines and CNS disorders would likely reveal a family of related patents, potentially covering intermediates, analogs, or different salt forms.
Competitive Landscape and Generic Entry
The existence of this patent has historically created a barrier to entry for generic manufacturers seeking to market unapproved drug products containing the claimed compounds.
- Exclusivity Period: The patent granted Merck exclusive rights to make, use, sell, and import the claimed inventions in the United States until its expiration.
- Paragraph IV Certifications: For generic companies to launch their products before the patent's expiration, they typically file an Abbreviated New Drug Application (ANDA) and challenge the validity or inventorship of the patent(s) held by the innovator. This often involves filing a "Paragraph IV certification" with the U.S. Food and Drug Administration (FDA), stating that their proposed product does not infringe the patent or that the patent is invalid. Such challenges frequently lead to patent litigation.
Post-Expiration Landscape
Upon the expiration of US Patent 7,420,069, the compounds and formulations claimed therein generally enter the public domain. This opens the door for generic manufacturers to seek FDA approval to market their versions of the drug, provided they meet all regulatory requirements and do not infringe on any other valid and unexpired patents (e.g., formulation patents, process patents with later expiration dates, or patents on specific polymorphic forms).
Key Takeaways
- United States Patent 7,420,069 covers a class of imidazo[1,2-a]pyridine derivatives and their use in treating neuropsychiatric disorders and pain.
- The patent claims specific chemical structures and pharmaceutical compositions containing these compounds, primarily designed as selective serotonin reuptake inhibitors (SSRIs).
- Assigned to Merck & Co., Inc., the patent's expiration date is March 20, 2027, barring any extensions, after which the claimed subject matter may become available for generic competition.
- The patent's broad scope and the innovator assignee suggest significant R&D investment and a strategic effort to protect a therapeutic platform in the CNS drug market.
FAQs
What is the primary therapeutic target of the compounds claimed in US Patent 7,420,069?
The primary therapeutic target is the serotonin transporter (SERT), with the compounds acting as selective serotonin reuptake inhibitors (SSRIs).
What specific neuropsychiatric disorders are mentioned as treatable by the compounds in this patent?
The patent mentions depression, anxiety disorders, panic disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).
When does United States Patent 7,420,069 expire?
The statutory expiration date for United States Patent 7,420,069 is March 20, 2027, assuming no patent term extensions are granted.
Can generic versions of drugs based on the compounds claimed in this patent be marketed before its expiration?
Generic versions generally cannot be marketed without regulatory approval and may infringe on the patent. Generic companies typically challenge patent validity or non-infringement to launch products before patent expiration, often through Paragraph IV certifications.
Does the patent claim only the active pharmaceutical ingredients, or also how they are administered?
The patent claims both the active pharmaceutical ingredients (compounds) and pharmaceutical compositions containing these compounds along with acceptable carriers, diluents, or excipients.
Citations
[1] United States Patent 7,420,069. (2008). Imidazo[1,2-a]pyridine derivatives. Retrieved from USPTO Patent Full-Text and Image Database.
